Neurocrine (NBIX) Maintained at Underperform by BMO, PT Hiked to $74, Analyst Sees Challenging Q1
Tweet Send to a Friend
BMO Capital Evan David Seigerman reiterates Underperform rating on Neurocrine Bio. (NASDAQ: NBIX) but increases price target to $74.00 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
